GV, formerly known as Google Ventures, hired biotechnology industry veteran David Schenkein to co-lead the company's life sciences investments, according to Bloomberg.
Mr. Schenkein previously served as CEO of Agios Pharmaceuticals before stepping down in 2018. He is still chairman of Agios.
GV is the venture capital arm of Google parent Alphabet.
"I can't think again of any other firm that has as broad a remit in healthcare," Mr. Schenkein told Bloomberg. "It's the delivery of healthcare, it's the insurance of healthcare, it's healthcare broadly."